Vitamed Galaj I Cichomski Sp. j.
- Address
- lock Available on a paid plan
Gastroenterology and Digestive Health
At Vitamed Galaj I Cichomski Sp. j. in Bydgoszcz, clinical research in gastroenterology focuses on digestive system diseases and related physiological processes, especially ulcerative colitis and eosinophilic esophagitis. These studies are designed to evaluate new treatments, improve long-term disease control, and better understand how therapies support patients living with chronic inflammatory conditions.
- Moderately to severely active ulcerative colitis
- Eosinophilic esophagitis
- Evaluation of treatment effectiveness and long-term safety
The site contributes to research aimed at improving symptom control, maintaining remission, and expanding options for patients with ongoing gastrointestinal inflammation.
Respiratory and Pulmonary Diseases
A major part of the trial portfolio at this Polish site covers respiratory tract diseases, with emphasis on idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, asthma, and other chronic lung conditions. The studies are exploring whether new therapies can preserve lung function, reduce disease progression, and improve day-to-day breathing outcomes.
- Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
- Asthma and chronic cough
- Testing new treatments and assessing lung function benefits
This research also includes work in interstitial lung diseases and pulmonary sarcoidosis, reflecting a strong focus on difficult-to-treat respiratory disorders.
Neurology and Brain Health
The site is also involved in nervous system diseases, including migraine, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and rare seizure disorders. These trials are generally intended to evaluate symptom relief, disease progression, and the longer-term safety of emerging therapies.
- Migraine prevention and acute treatment
- Multiple sclerosis and Parkinson’s disease
- Alzheimer’s disease and rare epilepsy syndromes
Research in this area supports efforts to improve quality of life for people with chronic and often progressive neurological conditions.
Skin, Allergy, and Immune-Mediated Conditions
Clinical trials at Vitamed Galaj I Cichomski Sp. j. also address skin and connective tissue diseases and immune system diseases, including acne vulgaris, atopic dermatitis, and plaque psoriasis. The main goal is to test new therapies and assess whether they can provide better control of inflammatory skin symptoms with acceptable safety.
- Acne vulgaris
- Atopic dermatitis and plaque psoriasis
- Evaluating safety, tolerability, and clinical benefit
This area of research reflects a broader interest in immune-driven conditions that affect both comfort and quality of life.
Cardiovascular and Musculoskeletal Research
The trial portfolio includes studies in cardiovascular diseases and musculoskeletal diseases, such as recent myocardial infarction with iron deficiency and knee osteoarthritis. These trials aim to determine whether new or repurposed treatments can improve recovery, reduce complications, and support physical function.
- Recent myocardial infarction with iron deficiency
- Mild non-serious osteoarthritis of the knee
- Assessing recovery, mobility, and quality of life
The studies highlight an interest in both post-event cardiovascular care and symptom management for common joint disease.
Infectious Disease and Vaccine Research
Another research theme at the site involves bacterial infections and mycoses, with studies related to meningococcal infection and respiratory tract infections. These trials focus on vaccine effectiveness and prevention strategies, aiming to strengthen protection against infectious disease in children and healthy volunteers.
- Meningococcal vaccination research
- Prevention of respiratory tract infections in children
- Evaluating immune response and protective benefit
This work supports public health efforts by studying how well preventive approaches can reduce infection risk across different age groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG8trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vitamed Galaj I Cichomski Sp. j.
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ADMILPARANT | 3 | Unknown | 2024-06-24 | 2024-07-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
